This year has yet to see a blockbuster-style deal, but prices remain punchy nevertheless.
Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.
Calliditas is hoping for its first approval, while Abbvie is gearing up to enter the crowded migraine space with an oral anti-CGRP project.
Since 2016 drug developers have spent $23.6bn in-licensing cancer projects, almost half of the sector’s up-front bill.
Curiously, the $900m acquisition will not include many of Teneobio’s pipeline projects.
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.